Novo Nordisk highlights several limitations of study linking Ozempic and Wegovy to sight loss
The study is not designed to show a causal relationship with the eye condition, the pharmaceutical company points out.
by MARKETWIRE
Novo Nordisk sees a number of methodological limitations associated with the study that suggests a risk that Novo Nordisk’s best-selling diabetes 2 drug Ozempic and weight loss drug Wegovy are associated a rare type of vision loss.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
